Caribou Biosciences Appoints Reigin Zawadzki as Chief People Officer
September 27 2023 - 7:00AM
Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading
clinical-stage CRISPR genome-editing biopharmaceutical company,
today announced the appointment of Reigin Zawadzki to the newly
created position of chief people officer. Ms. Zawadzki brings over
20 years of experience leading human resources in the biotechnology
industry. She will lead Caribou’s people strategy and report to
Rachel Haurwitz, PhD, president and chief executive officer.
“Reigin is an experienced human resources leader who has an
impressive track record in leading human resource strategies that
are closely aligned with the mission, values, and culture of an
organization,” said Rachel Haurwitz, PhD, Caribou’s president and
chief executive officer. “Her role as an executive leader at
Caribou will be invaluable in maintaining our strong culture and
supporting our teams as we develop our pipeline of allogeneic CAR-T
and CAR-NK cell therapies for patients with hematologic
malignancies and solid tumors. With Caribou now established as a
clinical-stage company, we next aim to position our organization
for future commercialization, and we are delighted to welcome
Reigin as our first CPO.”
“I am excited to join Caribou, a CRISPR genome editing pioneer
and a leader in the allogeneic cell therapy field,” said Reigin
Zawadzki, Caribou’s chief people officer. “As I embark on this
incredible journey with the talented team at Caribou, I am honored
to lead the overall people strategy and work to maintain and
develop an exceptional, diverse, and inclusive culture as the
company continues to advance.”
Reigin Zawadzki, chief people officer, Caribou
BiosciencesA photo accompanying this announcement is
available
athttps://www.globenewswire.com/NewsRoom/AttachmentNg/fdee4c82-8c16-40bd-8588-8cdb98a0755d
Reigin Zawadzki joins Caribou from Theravance Biopharma, where
she was vice president and chief human resource officer and served
in roles of increasing responsibility, supporting the organization
through multiple stages of growth. At Theravance, she was
responsible for organizational design, training and development,
talent acquisition, employee engagement, legal compliance, and
total rewards. She has a proven track record for creating talent
and culture practices that result in positive employee experiences
that enable people to thrive. She understands the significance of
having a diverse and inclusive culture to attract and retain great
people and drive corporate goals and results. She began her career
in recruiting at Heidrick & Struggles. Ms. Zawadzki earned a BS
from the Ohio State University.
About Caribou’s novel next-generation CRISPR
platformCRISPR genome editing uses easily designed,
modular biological tools to make DNA changes in living cells. There
are two basic components of Class 2 CRISPR systems: the nuclease
protein that cuts DNA and the RNA molecule(s) that guide the
nuclease to generate a site-specific, double-stranded break,
leading to an edit at the targeted genomic site. CRISPR systems are
capable of editing unintended genomic sites, known as off-target
editing, which may lead to harmful effects on cellular function and
phenotype. In response to this challenge, Caribou has developed
CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”)
that direct substantially more precise genome editing compared to
all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA
technology to carry out high efficiency multiple edits, including
multiplex gene insertions, to develop CRISPR-edited therapies.
About Caribou Biosciences, Inc.Caribou
Biosciences is a clinical-stage CRISPR genome-editing
biopharmaceutical company dedicated to developing transformative
therapies for patients with devastating diseases. The company’s
genome-editing platform, including its Cas12a chRDNA technology,
enables superior precision to develop cell therapies that are
armored to potentially improve antitumor activity. Caribou is
advancing a pipeline of off-the-shelf cell therapies from its CAR-T
and CAR-NK platforms as readily available treatments for patients
with hematologic malignancies and solid tumors. Follow us
@CaribouBio and visit www.cariboubio.com.
Caribou Biosciences, Inc.
Contacts:Investors:Amy Figueroa,
CFAinvestor.relations@cariboubio.com
Media:Peggy Vorwald,
PhDmedia@cariboubio.com
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Apr 2024 to May 2024
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From May 2023 to May 2024